Pardthaisong T, Yenchit C, Gray R
Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Contraception. 1992 Apr;45(4):313-24. doi: 10.1016/0010-7824(92)90053-v.
Children exposed to the injectable contraceptive Depo-Provera (DMPA) during pregnancy (N = 1,207), and/or during breastfeeding (N = 1,215) were exposures during pregnancy or breastfeeding. Weights and heights were measured for all children, and information on signs of puberty obtained for children aged ten and over. Cross-sectional weights and heights by age of DMPA-exposed children were similar to those for controls. Children with DMPA exposure during pregnancy and lactation had an increased risk of suboptimal growth in height, defined as less than two Z scores on NCHS standards (RR = 1.4, 95% CI 1.2-1.8). However, after adjustment for socioeconomic factors by multiple logistic regression, there was no increased risk of impaired growth among the DMPA-exposed children (RR = 1.1, 95% CI 0.8 - 1.6). With the exception of a delay in onset of reported pubic hair growth among DMPA-exposed girls, there were no significant effects on attainment of puberty. We conclude that use of DMPA during pregnancy or breastfeeding does not adversely affect the long-term growth and development of children.
在孕期（N = 1207）和/或哺乳期（N = 1215）接触过注射用避孕药醋酸甲羟孕酮（Depo - Provera，DMPA）的儿童，属于孕期或哺乳期接触情况。对所有儿童测量了体重和身高，并获取了10岁及以上儿童的青春期体征信息。DMPA暴露儿童按年龄划分的横断面体重和身高与对照组相似。孕期和哺乳期接触DMPA的儿童身高生长欠佳风险增加，身高生长欠佳定义为低于美国国家卫生统计中心（NCHS）标准的两个标准差（风险比[RR] = 1.4，95%置信区间[CI] 1.2 - 1.8）。然而，通过多因素逻辑回归对社会经济因素进行调整后，DMPA暴露儿童生长受损风险未增加（RR = 1.1，95% CI 0.8 - 1.6）。除了DMPA暴露女孩报告的阴毛生长开始时间延迟外，对青春期发育没有显著影响。我们得出结论，孕期或哺乳期使用DMPA不会对儿童的长期生长和发育产生不利影响。
